Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Medical Device Startup Investors in Switzerland in January 2025

Last updated: Jan 2025 A list of 50 angel investors and VC (Venture Capital) funds that invest in Medical device startups based in Switzerland. We rank investors based on the number of investments they made in Medical device companies from Switzerland. We update this investor list every month.

Top 50 Medical Device Startup Investors in Switzerland in January 2025

Investor	Medical Device Switzerland investments
Zürcher Kantonal Bank	24
Foundation for Innovation and Technology (FIT)	14
Verve Ventures	13
VI Partners	9
StartAngels Network	7
redalpine	5
BioMedPartners	5
OCCIDENT	5
4FO Ventures	4
Zühlke Ventures AG	4
Translink Capital	4
EIT Health	3
3wVentures	3
Fongit Seed Invest	3
Neomed Management	3
EVA Basel	3
415 Capital	3
BlueOcean Ventures	3
Alpana Ventures	3
Innosuisse	3
M Ventures	3
VitaTech S.A	2
Kinled Holding	2
New Enterprise Associates	2
SICTIC	2
Christian Wenger	2
Molten Ventures	2
Initiative Capital Romandie	2
TiVentures	2
Inkef	2
Polytech Ventures	2
Schroder Adveq	2
Sofinnova Partners	2
Swisscom Ventures	2
Dominik A. Lysek	2
Forward Venture Capital	1
Khosla Ventures	1
Astanor Ventures	1
Lichtsteiner Foundation	1
NEST pension fund	1
Supermoon Capital	1
HBM Partners	1
Technology Fund	1
Schroders	1
Think.Health	1
BB Biotech Ventures	1
Simon Michel	1
Bruker	1
N&V Capital	1
Zürcher Kantonalbankand	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Series A, Funding Round
Switzerland, Japan, Spain

Portfolio highlights

Somagenetix — Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases.
Retinai — RetinAI optimises and simplifies clinics, research and pharmaceutical workflows to improve healthcare. To achieve this goal, the company builds tools to collect, analyze and organize health data, empowering healthcare professionals and patients with automatic image and data analysis supported by advanced machine learning. RetinAI has proprietarytechnology that provides unforeseen image quality enhancement, as well as automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies and device manufacturers at similar level of performance as a human would produce.
Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.

The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.

Investment focus

Health Care, Biotechnology, Software
Debt Financing, Grant, Seed
Switzerland, France

Portfolio highlights

Aspivix — ASPIVIX is developing a new generation of medical devices that make gynecological procedures gentler and safer for women and gynecologists. The first device, CAREVIX, is designed to prevent cervix bleeding using a suction technology to replace traumatic tenaculum (forceps).
Xemperia — Xemperia provides diagnostic solutions that helps to detect breast cancer and early diagnosis of relapses.
Ex Nunc Intelligence — Ex Nunc Intelligence provides professionals with thorough summaries of legal information, credible responses to legal issues, and automated legal document preparation features.

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, France, Germany

Portfolio highlights

Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
tozero — Truly bringing lithium-ion battery waste tozero by recovering all critical matierlas, like lithium, nickel, cobalt, manganese, and graphite.
Orakl Oncology — Cultivated with love by the Orakl team.

VI Partners are Venture Capitalists successfully financing outstanding teams and innovations in the Healthcare and Technology space since 20 years.

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B, Series C
Switzerland, Germany, United States

Portfolio highlights

Oplit — Oplit is a production planning platform that provides software and support to help industrials boost operations profitability.
XO Life — XO Life is to build the largest real-world evidence platform for patient insights for all medications and therapies. Together with one of Europe's leading research institutes for patient-centered research, the PROMIS Institute Germany of the Charité, and various pharmaceutical manufacturers, patient experiences are to be recorded in astandardized and systematic manner across a wide range of diseases. Patients are to be enabled to record their therapy course and outcome independently as well as scientifically validated so that these patient insights from real treatment practice can be used in the life science industry and by medical professions.
Somagenetix — Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases.

StartAngels Network is a Zurich-based angel investment firm that provides investment consulting services.

Investment focus

Medical Device, Health Care, Medical
Seed, Series A, Series B
Switzerland, Brazil

Portfolio highlights

Medyria — Medyria is a Swiss medtech startup that engineers technologies for cardiovascular catheter navigation and sensing. They develop a unique guiding and sensing medical device based on proprietary Blood Flow Velocity Sensor technology. The TrackCath System is designed to be cost-effective and safe during EVAR procedures.Medyria's goal is todevelop devices that enable safer and more effective endovascular procedures. It was founded in 2014 and is based in Winterthur, Zurich, Switzerland.
Pipra — PIPRA AG (Pre-Interventional Preventive Risk assessment) is developing a cutting-edge AI-based pre-operative test to assess a patient's risk of suffering from cognitive disorders after surgery.
Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.

redalpine is a thesis-driven vc with deep expertise in software and science. since 2006. we believe in the power of big ideas and in empowering game changers. we don't just invest, we co-create a better tomorrow. together with you.

Investment focus

Biotechnology, Software, Health Care
Series A, Seed, Series B
Germany, Switzerland, United Kingdom

Portfolio highlights

9fin — 9fin is a leading provider of debt market intelligence and offers everything you need to analyse a credit, or win a mandate in one AI-powered platform
Apaleo — Transform your hospitality business with an open platform. Easily connect 3rd party applications to build a best-in-class tech stack for your hotel
OrthoPulse — OrthoPulse is a medical device manufacturer that produces dental care equipment, treatment control apps, and photo biomodulation solutions.

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Switzerland, Germany, France

Portfolio highlights

ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
TOLREMO therapeutics — TOLREMO therapeutics is striving to prevent the development of cancer therapy resistance through its proprietary drug discovery and development platform. Learn more about us.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments. Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.

Investment focus

Health Care, Medical Device, Biotechnology
Series A, Series B, Series C
Germany, Switzerland, Slovenia

Portfolio highlights

ReCatalyst — REvolutionizing the way we make CATALYSTs for hydrogen technologies
Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

4FO Ventures

Investment focus

Artificial Intelligence, Health Care, Medical
Series A, Seed, Series B
Switzerland

Portfolio highlights

Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
Ecorobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.

Zühlke Ventures AG is a venture capital arm of Zühlke Technology Group AG specializing in financing of start-ups at an early stage and providing growth capital. It seeks to invest in the technology and medical devices companies. It typically invests in German-speaking Europe and Great Britain.

Investment focus

Health Care, Medical Device, Biotechnology
Series A, Seed, Series B
Switzerland, Sweden, United States

Portfolio highlights

Evismo — Evismo provides diagnostics services in Switzerland
Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
Flow Neuroscience — Flow Neuroscience is a healthcare company that develops depression treatment devices that combines an easy-to-use brain stimulation headset with a personalized mobile app to target both the physical and behavioral elements of Major Depressive Disorder (MDD). The company's wearable stimulates a patient's left frontal lobe, the area of thebrain that has often lowered activity in people suffering from depression.Flow Neuroscience combines their wearable with a mobile app that nudges users to behaviors that will help lessen the effects of their depression, including exercise and regular sleeping patterns.The company's hope is to make available for the public a treatment that's currently only used in clinics specialized in brain stimulation. It also wants to make the treatment affordable enough to seriously challenge a dominant pharmaceuticals industry.

Translink Capital is a trailblazing Silicon Valley VC with unmatched institutional connections to Asia's economic powerhouses.

Investment focus

Software, Information Technology, Artificial Intelligence
Series A, Series B, Series C
United States, China, South Korea

Portfolio highlights

Sakana AI — We are creating a new kind of foundation model based on nature-inspired intelligence.
TensorWave — Access AMD MI300X GPUs today on TensorWave Cloud. Contact us today to get started.
Spectro Cloud — Enterprise Kubernetes management platform built for scale. Complete lifecycle management of any type of cluster, from bare metal to the edge.

EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.

Investment focus

Health Care, Medical Device, Medical
Grant, Pre-Seed, Seed
United Kingdom, Spain, Ireland

Portfolio highlights

Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
Trak — Trak is a software tool for healthcare professional to provide AI-based tele-rehabilitation services like physiotherapy and others.
Nanordica Medical — Nanordica Medical develops novel nanoparticle-based antibacterial wound care products.

3wVentures provides seed money and venture capital to international internet startups. As they focus on early stage projects and prototypes, our investments and co-investments target a volume of up to USD 250,000.

Investment focus

Software, Health Care, Information Technology
Seed, Angel, Series A
Switzerland, Spain, Austria

Portfolio highlights

Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:
GUURU — GUURU's Community Solution enables trustworthy and authentic live conversations between shoppers and your customer community.
Pregnolia — Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete theclinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.

Investment focus

Health Care, Medical, Biotechnology
Seed, Series A, Series B
Switzerland

Portfolio highlights

EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series C, Funding Round
Switzerland, United States, Italy

Portfolio highlights

Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
Oxular — Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
JenaValve Technology — Redefining what it means to treat patients with severe aortic regurgitation.

EVA is sparring partner for new entrepreneurs in the Life Sciences with planned base in north-western SwitzerlandThey support start-ups by helping to bridge the gap between their business idea and the successful commercialization of their life sciences projects, innovations and technologies.They provide thorough coaching and activelyencourage contact with their wide-ranging network of experts and investors as well as providing seed-phase investments.In science and technology transfer, they act as the link between researchers, universities’ scientific liaison offices, potential investors and the market.

Investment focus

Biotechnology, Medical Device, Medical
Seed, Series A
Switzerland

Portfolio highlights

AOT - Advanced Osteotomy Tools — AOT AG is a privately owned Swiss Robotic Surgery company, which spun out of the University Hospital and the University Basel (Switzerland) in 2011 and was first funded in 2012. The company is dedicated to the development, manufacturing and sales of medical devices for osteotomy pursuing the vision of contact-free bone surgery using laser,robotics and navigation systems to re-invent bone surgery (osteotomy).
POLYNEURON — Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patientswith immune disorders in a safe and effective manner.
Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

415 CAPITAL is a specialist venture capital firm that invests in early- and development-stage MedTech companies in Europe, the United States and Israel.They primarily invest in innovative medical device technologies addressing cardiovascular disease: the worldwide leading cause of death and the single largest cost driver in the global healthcaresystem.We are investors AND entrepreneurs: As investors, They have funded 45 MedTech companies in the past 28 years. As entrepreneurs, They have founded, built, and exited several successful European MedTech distribution companies.

Investment focus

Medical Device, Health Care, Medical
Series A, Series C, Seed
Switzerland, United States, France

Portfolio highlights

Aktiia — Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com.
Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
CorFlow Therapeutics AG — CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients.

BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.

Investment focus

Health Care, Medical, Biotechnology
Series A, Seed, Series B
Switzerland, India, France

Portfolio highlights

nPloy — Simply set your filters and get matched with your dream job! Let top employers apply for you & connect with them via chat or a video call.
CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors

Alpana Ventures is a Swiss VC focusing on digital transformation.Since 2016 we backed 45 founder teams with 3 Funds, supporting them in their journey towards a positive impact.Committed to value creation, we discover deep tech solutions in Switzerland, Europe and the US.We invest to embed them into innovative business models and back them tobecome global market leaders.Applying ESG criteria, our portfolio companies help create a more sustainable future.

Investment focus

Software, FinTech, Information Technology
Seed, Series A, Funding Round
United States, Switzerland, Germany

Portfolio highlights

Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
Nezasa — Discover how to grow your business with Nezasa TripBuilder, the world's leading travel commerce solution for travel businesses.
Tinamu — Tinamu Labs has developed a technology that converts commercially available drones into camera equipment reaching professional standards.

Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland.

Investment focus

Health Care, Biotechnology, Medical Device
Grant, Pre-Seed, Seed
Switzerland, United States, United Kingdom

Portfolio highlights

Picterra — Transform your business with Picterra's cloud-native AI platform. Optimize geospatial workflows, detect objects faster, & drive sustainable action.
LatticeFlow — LatticeFlow is empowering organizations to build and deploy robust AI they can understand and trust.
csky.ai — A unique, private-by-design solution for secure transcription, automated note-taking, compliant reporting, and more. With on-device AI, your data never leaves the room.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Enara Bio — Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-relatedDNA sequences.
IonKraft — IonKraft can provide better performance at a lower cost while maintaining recyclability, they also promote material reduction and reuse and are commercializing the technology with funding from the German Federal Ministry for Economic Affairs and Energy (BMWi).
Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.

VitaTech S.A

Investment focus

Medical Device, Biotechnology, Therapeutics
Series A
Switzerland, United States

Portfolio highlights

Aesyra — Aesyra makes innovative medical devices to help manage bruxism and improve your sleep.
Gain Therapeutics — Discover Gain Therapeutics' next-gen allosteric small molecule therapies, combining physics-based methods and AI to address critical patient needs.
Industrie Biomediche Insubri — IBI is an innovative hi-tech Swiss biomedical company focused on research, development and production of medical devices for tissue engineering and regenerative medicine: substitutes, grafts, 3D matrixes and 2D scaffolds.

Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.

Investment focus

Biotechnology, Health Care, Financial Services
Seed, Funding Round, Series A
United Kingdom, United States, Switzerland

Portfolio highlights

Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
OneTrust — OneTrust is a provider of privacy management and marketing compliance technology that helps organizations comply with global regulations. It automates privacy impact assessments and data inventory mapping, enforces risk remediation actions, and triggers recurring audits for continuous compliance monitoring across customer, employee, and vendor datatransfers. Its web-based software can be accessed on any device and provides a single place for a private office to collaborate with business groups, vendors, and trusted advisors managing privacy risks. The result is the ability to demonstrate privacy by design and ongoing compliance with policies, data privacy laws (GDPR, BCR, Privacy Shield), and other privacy frameworks (HITECH, ISO, GAPP, APEC).The company was founded in 2016 and is headquartered in Atlanta, Georgia.
Connect Earth — Connect Earth is an environmental data company that builds the infrastructure for climate-conscious products by aggregating and standardising environmental data and making it available through developer-first toolkits. The core product is an API solution that calculates the carbon impact of spend-based financial transactions of consumers and companies.

Foundational partners to ambitious founders at every stage of company-building.

Investment focus

Software, Health Care, Biotechnology
Series B, Series A, Series C
United States, India, China

Portfolio highlights

FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Ouro Medicines — Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline.
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.

Swiss ICT Investor Club (SICTIC) connects smart money investors to Swiss seed and early-stage tech startups.

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Pre-Seed, Funding Round
Switzerland, Germany, United Kingdom

Portfolio highlights

Pelt8 — Pelt8 enables climate action through the platform with scalable processes and controls to collect sustainability-related data in an easy and traceable way.
Creaitor — Creaitor is the ultimate solution for content producers, offering a comprehensive suite of AI tools and integrated SEO features. Streamline your content creation process and optimize your online presence with our powerful platform.
Health Yourself — Health Yourself is making routine healthcare services available digitally and from home. So far, we are offering lab tests from home, medication subscriptions and personalised supplements for health concerns ranging from sexual health to prevention.

Christian Wenger - Chairman @ Startup INVEST

Investment focus

SaaS, Internet, Software
Seed, Series A
Switzerland, Germany, Australia

Portfolio highlights

Aktiia — Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com.
Kollabo — Kollabo - the deep job platform for skilled blue collar workers. Thanks to our large network of temporary offices & our qualified team, we excel at finding the perfect match for job seekers and staffing agencies. Never before has the recruiting process been so easy and hassle-free for everyone involved. The goal is to digitally enable allstakeholder, generating a win-win-win situation. It can be that simple with Kollabo – We make work easy.
ExpressSteuer — ExpressSteuer is building AI-powered software that simplifies and automates the process of filing a german tax return which is considered to be the most complex and complicated in the world.

Molten Ventures is a venture capital company. They invest in software, telecoms, electronics, the internet, MedTech, and cleantech services. They support visionary entrepreneurs who will invent the future.

Investment focus

Software, Information Technology, Financial Services
Series A, Series B, Funding Round
United Kingdom, United States, Germany

Portfolio highlights

PocDoc — PocDoc is a pioneer in the field of smartphone-based fast disease testing.
FintechOS — FintechOS extends your core, letting you innovate banking and insurance products, digital journeys, and back-office workflows without the cost or risk.
SatVu — SatVu captures high resolution thermal data from space for a safer and more sustainable Earth.

Initiative Capital Romandie is a private equity fund that focuses on technology companies based in Western Switzerland.

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B, Series E
Switzerland

Portfolio highlights

PicoDRILL — PicoDRILL generates technology leadership for its partner/customers through cutting-edge technology for drilling needs in the nanotechnology field. picoDrill is a private company located in Lausanne, Switzerland.
Diagnoplex — Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert RÃ¼f Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as wellas its high sensitivity and specificity.
Aleva Neurotherapeutics — Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity,translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage.Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use.Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified.

TiVenture is a seed investment fund owned by the Fondazione Centenario Banca Stato that invests in early stage companies with innovative technologies and high growth potential, principally in southern Switzerland. TiVenture is actively looking and ready to support exceptional founders and entrepreneurs developing scalable products for the globalmarket. TiVenture has a diversified portfolio of companies and is mainly active in the life science, medical, high-tech and IT sectors.

Investment focus

Software, Analytics, Renewable Energy
Seed, Series A, Funding Round
Switzerland, Italy, United States

Portfolio highlights

Hoxell — Hoxell is an intuitive and easy-to-use integrated platform that digitizes and streamlines all hospitality operations.
Hive Power — Hive Power provides a SaaS platform to optimise your existing electrical distribution grid, both from the technical and economic points of view.
Gaia Turbine — Gaia Turbine SA - High-Performance Hydroelectric Turbine for micro and mini power plants

SVB - Europe's biggest online shop for boating equipment and accessories! Worldwide delivery, even directly on-board!

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
The Netherlands, United States, Germany

Portfolio highlights

Onward — Working to restore movement, independence, and health in people with spinal cord injury.
Draupnir Bio — Draupnir Bio is developing new innovative therapies for patients.
Provable Markets — A comprehensive suite of trading & trade management solutions for the front, middle, and back office

Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world

Investment focus

Financial Services, FinTech, Software
Seed, Series A, Funding Round
Switzerland, United States, Spain

Portfolio highlights

yamo — Frische Bio-Kindernahrung von yamo, so lecker wie selbstgemacht und kostenlos direkt zu dir nach Hause geliefert. Jetzt probieren und profitieren.
Relai — Relai is the easiest way to invest in Bitcoin for the long-term investor. A simple and intuitive app that allows users to buy and sell Bitcoin directly from their bank account within 1 minute, without registration, KYC verification or deposits. It was founded in 2019 and is headquartered in Zurich, Switzerland.
Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle

Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Series A
Switzerland, United States, India

Portfolio highlights

Bizongo — Bizongo is a Tech-Enabled B2B Platform for Packaging, Apparels & Other Customised Goods. We digitally transform vendor management & supply chain.
Lenskart — Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399, all this while you sit in the comfort of your home. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able todo in India yet.The website has over 500 designs of eye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery.Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision are to name a few) and be it disposable, toric, colored or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
Noema Pharma — BEYOND SYMPTOM CONTROL Developing therapies to help both orphan and larger patient populations with conditions of the brain and nervous system live their li ...
Tenpoint Therapeutics — Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.

Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.

Investment focus

Software, SaaS, Information Technology
Funding Round, Series B, Series A
Switzerland, United States, United Kingdom

Portfolio highlights

xFarm Technologies — The agricultural business is becoming more and more complex due to legal requirements and product certification. On the other hand, technologies evolve and create opportunity. xFarm is a startup that aims at the digitization of agriculture, providing innovative tools that can support farmers and food supply chain's stakeholders in themanagement of their companies. Created by farmers and tailored to the agricultural sector, its main focus is on ease of use, intuitiveness and complete adaptability to agricultural realities. The digital ecosystem includes a free agricultural application, available on both mobile and desktop and integrated with advanced premium modules, a dashboard Analytics dedicated to professionals and a line of IoT sensors selected, optimized and connected by xFarm.
ANYbotics — ANYbotics provides autonomous legged robots for industrial applications to provide high availability and reliability in automated routine inspections.
Kyan Health — Prioritise your employees' mental health and well-being with Kyan Health. Our evidence-based solutions address employees' mental well-being, stress at work & boost your workforce productivity.

Dominik A. Lysek - Co-CSO @ vVardis

Investment focus

Wellness, Health Care, Medical Device
Seed
Switzerland

Portfolio highlights

Odne — Curing with light

Forward Venture Capital is a Venture Capital fund that invests in early-stage companies in the US and Europe. We support early stage entrepreneurs and help them accelerate their growth.

Investment focus

Software, Financial Services, E-Commerce
Seed, Series A, Pre-Seed
United States, Sweden, Denmark

Portfolio highlights

Uniify — Uniify is a no-code customer onboarding software that makes it fast, easy and secure for financial companies to onboard their customers. Save your business time and money, and build onboarding flows for your customers in minutes instead of months.
Niricson — Niricson Software has developed a proprietary damage assessment software platform paired with a patent-pending drone-based data collection technology that helps infrastructure owners inspect their structures (e.g. hydro dams) in a way that is more accurate, five times faster, and 50% more cost-effective. Niricson is differentiated by its ability toautomatically detect and quantify not only surface damage, but also subsurface damage.
Elements Advisors — Elements Vitals revolutionize the way you measure, benchmark, and monitor financial health. Save time serving clients & growing your firm.

Khosla Ventures invests in companies that are bold, early and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Headquartered in Menlo Park, Calif., Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech,digital health, medtech and diagnostics, therapeutics and frontier technology.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Series B, Seed
United States, India, United Kingdom

Portfolio highlights

Karius — Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a majorthreat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
Zeck — Create smarter, modern board updates optimized for superior readability to better engage and inform your board and investors. Run perfect board meetings.
YonedaLabs — Yoneda Labs suggests Reaction Conditions that work with no wet lab experimentation, and then we can help you optimise too, if necessary.

We help the ambitious build a food system that is nourishing, regenerative, scalable, trusted and produces delicious food for all.

Investment focus

Agriculture, Food and Beverage, Biotechnology
Series A, Seed, Series B
United States, France, United Kingdom

Portfolio highlights

Heali AI — Use food to treat or manage chronic health conditions using our unique personalised therapeutic nutrition plans powered by Heali Intel. Discover how evidence-based nutrition can control diabetes, heart health, and more. Start your wellness journey today. Find Heali on the app store today.
ProducePay — ProducePay provides a wide array of payment solutions to the fresh produce industry and its agents. Produce Pay was first conceived at Cornell University. With strong support from experienced faculty and the student body, it was able to rapidly gain momentum. Produce Pay obtained recognition from Cornell’s entrepreneurial community and was soondubbed "The Next Johnson Start-Up," in reference to Cornell’s S.C. Johnson Graduate School of Management.
BioFluff — SAVIAN EXPLORE SAVIAN

Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.

Investment focus

Medical, Health Care, Biotechnology
Seed, Series A
Switzerland

Portfolio highlights

Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
Testmate Health — Testmate Health is a medtech startup and award-winning spin-off of University of Geneva (Switzerland). We have developed a smartphone compatible platform test kit that diagnoses any disease with an identifiable DNA or RNA sequence - without the need for a lab, providing results directly at home in minutes. Based on this platform, our firstsolution is the first rapid urine self-test for the four most common sexually transmitted diseases (STD). One million new STDs are diagnosed a day, and yet the best improvements to date still need a lab, with results taking up to 7 days to be ready. Our easy to use all-in-one-kit provides results in minutes, anywhere, at any time, and the result is scannable by a smartphone to enable people to immediately gain access to treatment – if needed. Further test-kits with other diseases are in the pipeline to empower users to skip the waiting room, and take charge of their health from home.
Limula — Limula provides a unique platform technology enabling scale out of cell therapy production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments. Our patented solution is composed of an automation unit and single use kits, allowing healthcare providers to safely manufacture CGTin a decentralized manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production.

For more than 35 years, Nest, as the first ecological and ethical pension fund in Switzerland, has remained true to its guiding principle: the optimal provision for the companies affiliated with us and their employees.

Investment focus

Health Care, Biotechnology, Medical
Seed, Series A
Switzerland

Portfolio highlights

Piomic — There are about 50 million reported cases of patients suffering from hard-to-heal wounds, which has created a severe cost burden on global healthcare systems.The COMS® One Therapy System is a portable, hand-held device which incorporates the technologies for optical and magnetic stimulation, intended to promote wound healing in chronic leg andfoot ulcers.The pivotal clinical study showed that the treatment is safe, leads to accelerated wound closure, overall reduced pain and increased quality of life. The easy-to-use, single button operated device integrates smoothly into the patient’s healing journey with usage in stationary and ambulant facilities but also in patient’s home.By developing a therapy which is safe and effective we hope to set a better future for patients in need.
Comphya — CaverSTIM is a novel implantable device able to restore natural penile erection by neuromodulation.
Nagi Bioscience — Enabling small organisms testing to any lab. Unleash unique datapoints efficiently at a high-throughput rate.

Supermoon Capital is a specialist platform helping visionary founders enhance our lives, organizations, and communities through healthy sleep.

Investment focus

Health Care, Artificial Intelligence, Medical Device
Seed, Series A, Funding Round
Switzerland, United States, Israel

Portfolio highlights

Aesyra — Aesyra makes innovative medical devices to help manage bruxism and improve your sleep.
Arcascope — We create mobile apps based in circadian science to help people sleep and feel better.
Mosanna Therapeutics — Improving the lives of patients with metabolic obstructive sleep apnea using a transformative approach

HBM Partners focuses on venture, growth and buy-out financings of private companies as well as investments in public companies.The HBM funds invest in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. Their team supports the growth of the portfolio companies through allstages of development, focusing on adding value by leveraging its experience and HBM's world-wide network in the industry. Investments usually range between $5 million to $50 million.

Investment focus

Biotechnology, Medical, Health Care
Series B, Funding Round, Series C
United States, Germany, Switzerland

Portfolio highlights

Dren Bio — Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Neuron23 — Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Mineralys Therapeutics — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from MitsubishiTanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.

Climate protection through innovative technologies. The Technology Fund offers loan guarantees to Swiss companies whose novel products contribute to a sustainable reduction in greenhouse gas emissions

Investment focus

Information Technology, Software, Biotechnology
Debt Financing, Grant, Seed
Switzerland

Portfolio highlights

FGen — FGen is a Swiss start-up company founded 2011 in Basel as a spin-off from the Department of Biosystems Science and Engineering of the ETH Zurich. As a contract reasearch organization we collaborate with partners from Biotech, Life Sciences, and Pharma in order to establish efficient bioprocesses and to develop new biopharmaceuticals.
Calopad — Calopad, awarded by the Swiss Confederation, offers a unique and the most holistic solution in pain therapy and muscle regeneration. The therapeutic deep heat of 42 degrees solves any muscle pain, muscle tension, or muscle spasms of chronic patients in the long term and in a highly efficient way through new forms of therapy. With the associatedapp, Calopad brings the physiotherapist digitally into any user's home and enables personalized all-around care in real time - utterly independent of time and place. In the future, the modular design will make it possible to combine different therapies such as heat, cold, or light with just one device, opening up the possibility of new therapeutic successes.
Selfrag — SELFRAG AG is specialized in the development of high voltage pulse power products, plants and systems for selective fragmentation of solid materials.

As a global investment manager, we help institutions, intermediaries and individuals across the planet meet their goals, fulfil their ambitions, and prepare for the future.

Investment focus

Biotechnology, Financial Services, Medical
Series A, Series B, Series C
United Kingdom, India, Canada

Portfolio highlights

Firenze — Firenze aims to expand financial services by extending investment-backed lending to a wider audience, recognizing its importance in wealth creation and preservation. The founding team aims to democratize Lombard lending, making it accessible to all, while focusing on mass affluent clients.
Forteus — Forteus is an asset manager focused on blockchain technology and digital assets.
Redcliffe Labs — Redcliffe LifetechRedcliffe Lifesciences specializes in reproductive health testing, rare diseases, and cancer genetic diagnostics. The company offers a wide range of advanced products and services for healthcare companies, research institutions, and other public and private partnerships, such as testing using molecular and gene-based diagnostics,therapeutic molecules and advanced therapies, next-generation sequencing, and all bioinformatics services.

Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,

Investment focus

Health Care, Biotechnology, Medical Device
Seed, Series A, Series B
Germany, United States, Switzerland

Portfolio highlights

Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Navignostics — Navignostics combines highly multiplex tumor imaging with advanced data analytics for personalized cancer treatments.
Sphingotec GmbH — Improving patient outcomes with innovative diagnostics for critical care: Actionable insights in real-time

BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernseyâ€“based fund is advised by the Bellevue Asset Management Group, which has operations in CuraÃ§ao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated teamof investment advisors and an advisory board. In addition, it is supported by all of the Groupâ€™s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.

Investment focus

Biotechnology, Health Care, Medical
Series C, Series A, Funding Round
United States, Switzerland, Italy

Portfolio highlights

AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Moderna — Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies insidepatient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.
Aleva Neurotherapeutics — Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity,translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage.Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use.Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified.

Mr. Simon Michel has been the Chief Executive Officer of Ypsomed Holding AG since July 2014. Mr. Michel serves as a Senior Vice President of Marketing & Sales for Ypsomed Holding AG and is responsible for the business development and marketing of the injection, infusion and blood glucose meters as well as pen needles. He has been working withYpsomed since October 2006 and has been a Member of management since 2008. He served as a Finance Director of International, MIM at New Look Group Limited. He served as Senior Vice President of Marketing at Ypsomed Holding AG since October 2006 and also served as its Senior Vice President of Business Development. Mr. Michel served as Head of the Infusion Business Division at Ypsomed Holding AG. From 2003 to 2006, he worked for Orange Telecommunications in Zurich and Lausanne, was responsible for, among other things, the introduction and marketing of UMTS. Mr. Michel has been a Director of Sphinx Werkzeuge AG since 2006. He has been a member of executive committee of the local trade and industry association since 2008. He studied Masters with a focus on Media and Communications Management and Economics at the University of St. Gallen.

Investment focus

Robotics, Manufacturing, Medical Device
Series A
Switzerland

Portfolio highlights

LEM Surgical — We are developing the next generation of spine surgical robotic systems

Bruker Corporation is a provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.

Investment focus

Biotechnology, Medical, Health Care
Series A, Funding Round, Seed
United States, Switzerland

Portfolio highlights

KIYATEC — Kiyatec is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D cell culture technology platform. Kiyatec works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors.
Haystack Oncology — Haystack Oncology, an oncology company, uses the most recent circulating tumor DNA detection technology to enhance the diagnosis of minimum residual disease and provide superior therapy decision-making information.
Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.

N & V Capital is a family-owned venture capital boutique focused on European investments. With generations of entrepreneurial experience, we seek scalable ventures driven by technology or scientific progress. We engage primarily up to Series A rounds, preferring early-stage involvement to support visionary founders aiming for sustainablegrowth. Our commitment is for the long term, and we are driven by pragmatism, open-mindedness, and hands-on assistance wherever required.

Investment focus

Health Care, Leasing, Medical
Seed, Pre-Seed, Series A
Germany, Switzerland

Portfolio highlights

LeaseTeq — LeaseTeq bietet Privat- sowie Unternehmenskunden das erste komplett digitale Leasingangebot.
Likeminded — Likeminded developed a digital platform for mental health that gives people fast, low-threshold access to psychological support.
Virtonomy GmbH — Virtonomy is shortening time-to-market of medical products by conducting data driven studies on virtual patients.

Zürcher Kantonalbankand

Investment focus

Medical Device, Energy, Medical
Seed, Series A, Series B
Switzerland

Portfolio highlights

matriq — matriq offers innovative solutions for the part-individual marking of plastic components of all kinds. With the DynamicMold technology, marking takes place directly in the manufacturing machine, whether in injection molding, blow molding or thermoforming. Besides the application for traceability, the DynamicMold technology also offers thepossibility to integrate product protection.
Aspivix — ASPIVIX is developing a new generation of medical devices that make gynecological procedures gentler and safer for women and gynecologists. The first device, CAREVIX, is designed to prevent cervix bleeding using a suction technology to replace traumatic tenaculum (forceps).
Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.

Investors by industry